Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 10/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991534 | 1.00 | HDAC4 (0.44) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5993269 | 0.91 | HDAC1 (0.44) | HDAC4MEF2DHDAC1HDAC3HDAC8 | |
| SCHEMBL5993261 | 0.91 | HDAC1 (0.44) | HDAC4MEF2DHDAC1HDAC3HDAC8 | |
| SCHEMBL5995076 | 0.91 | HDAC1 (0.48) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5995067 | 0.91 | HDAC1 (0.48) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5994536 | 0.90 | HDAC1 (0.43) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5994528 | 0.90 | HDAC1 (0.43) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5991584 | 0.89 | HDAC1 (0.46) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5991577 | 0.89 | HDAC1 (0.46) | HDAC4MEF2DHDAC1KCNH2HDAC3 | |
| SCHEMBL5992938 | 0.86 | HDAC1 (0.47) | HDAC4MEF2DHDAC1KCNH2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | MKI67, PCNA, CCNA1 | HDAC4 341/4885MEF2D 2965/4885HDAC1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.